JNJ

225.85

-0.11%↓

ABT

91.74

-1.11%↓

MDT

83.27

+0.9%↑

A

120.69

-1.07%↓

VEEV

162.96

-2.86%↓

JNJ

225.85

-0.11%↓

ABT

91.74

-1.11%↓

MDT

83.27

+0.9%↑

A

120.69

-1.07%↓

VEEV

162.96

-2.86%↓

JNJ

225.85

-0.11%↓

ABT

91.74

-1.11%↓

MDT

83.27

+0.9%↑

A

120.69

-1.07%↓

VEEV

162.96

-2.86%↓

JNJ

225.85

-0.11%↓

ABT

91.74

-1.11%↓

MDT

83.27

+0.9%↑

A

120.69

-1.07%↓

VEEV

162.96

-2.86%↓

JNJ

225.85

-0.11%↓

ABT

91.74

-1.11%↓

MDT

83.27

+0.9%↑

A

120.69

-1.07%↓

VEEV

162.96

-2.86%↓

Search

MacroGenics Inc

Suletud

SektorTervishoid

3.42 -0.87

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

3.37

Max

3.52

Põhinäitajad

By Trading Economics

Sissetulek

-31M

-14M

Müük

-32M

41M

Aktsiakasum

-0.22

Kasumimarginaal

-34.333

Töötajad

293

EBITDA

-37M

-15M

Soovitused

By TipRanks

Soovitused

Osta

12 kuu keskmine prognoos

+82.42% upside

Dividendid

By Dow Jones

Järgmine tulemuste avaldamine

12. mai 2026

Turustatistika

By TradingEconomics

Turukapital

98M

221M

Eelmine avamishind

4.29

Eelmine sulgemishind

3.42

Uudiste sentiment

By Acuity

50%

50%

179 / 348 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Neutral Evidence

MacroGenics Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

23. apr 2026, 00:00 UTC

Uudisväärsed sündmused

Australian Flash PMI Bounce in April Conceals Deeper Worries

22. apr 2026, 23:33 UTC

Tulu

SK Hynix Posts Record Quarterly Results Amid AI Boom

22. apr 2026, 22:40 UTC

Tulu

Correction to ServiceNow Posts 22% 1Q Revenue Growth Article

22. apr 2026, 22:10 UTC

Omandamised, ülevõtmised, äriostud

ServiceNow Says $4 Billion Term Loan Credit Deal Will Help Finance Armis Security Deal

22. apr 2026, 21:11 UTC

Tulu

ServiceNow Posts 22% 1Q Revenue Growth, But Says Armis Deal Will Weigh on Margins

22. apr 2026, 21:01 UTC

Tulu

IBM Posts Higher 1Q Sales, Buoyed by AI -- Update

22. apr 2026, 23:46 UTC

Market Talk

Global Equities Roundup: Market Talk

22. apr 2026, 23:46 UTC

Market Talk

Nikkei May Remain Rangebound; Middle East Conflict in Focus -- Market Talk

22. apr 2026, 23:34 UTC

Market Talk
Uudisväärsed sündmused

Gold Falls as U.S.-Iran Cease-Fire Keeps Inflation Concerns High -- Market Talk

22. apr 2026, 23:16 UTC

Tulu

SK Hynix: Quarterly Revenue, Profits at All-Time High in 1Q

22. apr 2026, 23:15 UTC

Tulu

SK Hynix: Operating Profit Margin Reached Record 72% in 1Q

22. apr 2026, 22:54 UTC

Tulu

SK Hynix 1Q Net Profit Beat FactSet-Compiled Consensus

22. apr 2026, 22:54 UTC

Tulu

SK Hynix 1Q Net KRW40.346T Vs. Net KRW8.108T >000660.SE

22. apr 2026, 22:52 UTC

Tulu

SK Hynix 1Q Oper Pft KRW37.610T Vs. Pft KRW7.441T >000660.SE

22. apr 2026, 22:51 UTC

Tulu

SK Hynix 1Q Rev KRW52.576T Vs. KRW17.639T >000660.SE

22. apr 2026, 22:31 UTC

Tulu

Sandfire CEO: Delivery Risk, Input Cost Pressure Could Rise Quickly If Situation Deteriorates

22. apr 2026, 22:31 UTC

Tulu

Sandfire CEO: First, Second Order Impacts of Middle East Conflict Remain Hard to Predict

22. apr 2026, 22:30 UTC

Tulu

Sandfire CEO: Middle East Conflict Creates Significant Risk in Global Supply Chains

22. apr 2026, 22:30 UTC

Tulu

Sandfire: FY26 Underlying Operating Unit Costs Expected to 'Materially Aligned' With Guidance

22. apr 2026, 22:29 UTC

Tulu

Sandfire Resources 3Q Unaudited Underlying Ebitda $220 Million

22. apr 2026, 22:28 UTC

Tulu

Sandfire Resources 3Q Unaudited Sales Revenue $408 Million

22. apr 2026, 22:28 UTC

Tulu

Sandfire Resources 3Q Motheo Underlying Operating Unit Cost $44/Ton Ore Processed

22. apr 2026, 22:27 UTC

Tulu

Sandfire Resources 3Q Matsa Underlying Operating Unit Cost $95/Ton Ore Processed

22. apr 2026, 22:06 UTC

Market Talk
Tulu

Tesla Paid Robotaxi Miles Nearly Doubled Quarter-Over-Quarter -- Market Talk

22. apr 2026, 21:55 UTC

Omandamised, ülevõtmised, äriostud

ServiceNow Says $4B Term Loan Credit Deal Will Help Finance Armis Security Deal

22. apr 2026, 21:47 UTC

Tulu

Lam Research Stock Jumps on Strong Earnings -- Barrons.com

22. apr 2026, 21:37 UTC

Tulu

Texas Instruments Reports Solid Earnings. The Stock Is Up. -- Barrons.com

22. apr 2026, 21:34 UTC

Tulu

Tesla Surprises Wall Street With Better Profits, $1.4 Billion in Free Cash Flow -- 3rd Update

22. apr 2026, 21:29 UTC

Tulu

Lam Research Stock Jumps on Strong Earnings -- Barrons.com

22. apr 2026, 21:20 UTC

Market Talk
Tulu

Tesla Expands Manufacturing to Chips -- Market Talk

Võrdlus sarnastega

Hinnamuutus

MacroGenics Inc Prognoos

Hinnasiht

By TipRanks

82.42% tõus

12 kuu keskmine prognoos

Keskmine 6.33 USD  82.42%

Kõrge 9 USD

Madal 4 USD

Põhineb 4 Wall Streeti analüütiku instrumendi MacroGenics Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

4 ratings

2

Osta

2

Hoia

0

Müü

Tehniline skoor

By Trading Central

1.47 / 1.64Toetus ja vastupanu

Lühikene perspektiiv

Neutral Evidence

Keskpikk perspektiiv

Bullish Evidence

Pikk perspektiiv

Bearish Evidence

Sentiment

By Acuity

179 / 348 Pingereas Tervishoid

Uudiste sentiment

Neutral

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Alla keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest MacroGenics Inc

MacroGenics, Inc., a biopharmaceutical company, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. The company's pipeline of immuno-oncology product candidates includes MGC018, an antibody drug conjugate (ADC), which targets solid tumors expressing B7-H3; Enoblituzumab, a monoclonal antibody that targets B7-H3; and MGD024, an investigational bispecific CD123 × CD3 DART molecule to minimize cytokine-release syndrome for patients with hematologic malignancies. In addition, it develops Lorigerlimab, a monoclonal antibody that targets the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4; Tebotelimab, an investigational tetravalent DART molecule for PD-1 and lymphocyte-activation gene 3; Retifanlimab, a humanized monoclonal antibody targeting programmed death receptor-1; and IMGC936, an ADC that targets ADAM9, a cell surface protein over-expressed in various solid tumor types. Further, the company develops MGD014 and MGD020, a DART molecule to target the envelope protein of human immunodeficiency virus infected cells and CD3 on T cells; Teplizumab for the treatment of type 1 diabetes; and PRV-3279, a CD32B × CD79B DART molecule for the treatment of autoimmune indications. It has collaborations with Incyte Corporation; Zai Lab Limited; I-Mab Biopharma; and Janssen Biotech, Inc. The company was incorporated in 2000 and is headquartered in Rockville, Maryland.
help-icon Live chat